Johnson & Johnson Reports 6.8% Sales Growth to $24.0 Billion in Fiscal Third Quarter

Johnson & Johnson reported significant financial performance in its latest 10-Q filing for the fiscal third quarter ended September 28, 2025, with total sales reaching $24.0 billion, a 6.8% increase from $22.5 billion in the same period last year. The company's net earnings for the quarter were $5.2 billion, translating to a diluted earnings per share of $2.12, compared to $2.69 billion and $1.11 per share in the prior year. For the fiscal nine months, total sales amounted to $69.6 billion, up 5.0% from $66.3 billion, with net earnings of $21.7 billion, significantly higher than $10.6 billion in the previous year.

The company experienced notable changes in its financial metrics compared to the previous fiscal period. The gross profit margin improved to 69.6% in the third quarter, up from 69.0% a year earlier, while selling, marketing, and administrative expenses increased to $5.9 billion, reflecting a rise in investment related to recent acquisitions. Research and development expenses decreased to $3.7 billion, down from $4.9 billion, primarily due to the phasing of investments and the absence of significant prior year expenses related to acquisitions.

Strategically, Johnson & Johnson completed the acquisition of Intra-Cellular Therapies, Inc. on April 2, 2025, for approximately $14.5 billion, enhancing its portfolio in mental health therapeutics. The company also announced plans to separate its Orthopaedics business, targeting completion within 18 to 24 months. This strategic move aims to streamline operations and focus on core business areas. The company’s employee headcount remained stable, with no significant changes reported in staffing levels.

Operationally, the company reported a positive impact from acquisitions and divestitures, contributing to sales growth. The U.S. market saw a 6.2% increase in sales, while international sales grew by 7.6%. The Innovative Medicine segment, which includes oncology and immunology products, generated $15.6 billion in sales for the third quarter, a 6.8% increase year-over-year. However, the segment faced challenges from biosimilar competition, particularly affecting sales of STELARA, which declined by 41.3%.

Looking ahead, Johnson & Johnson anticipates continued growth driven by its diverse product portfolio and strategic acquisitions. The company remains cautious about potential impacts from market conditions, including pricing pressures and regulatory changes. The effective tax rate for the fiscal nine months was reported at 21.5%, up from 16.9% in the previous year, influenced by recent tax law changes. Overall, Johnson & Johnson's outlook reflects a commitment to innovation and operational efficiency while navigating the complexities of the healthcare market.